A Phase II Clinical Study for Evaluating the Efficacy and Safety of Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone in Transplantation-Eligible Elderly Patients with Newly Diagnosed Multiple Myeloma (KMM2101)

被引：0

作者：

Yoon, Sang Eun ^{[1
]}

Jung, Sung-Hoon ^{[2
]}

Lee, Gyeong Won ^{[3
]}

Min, Chang-Ki ^{[4
]}

Byun, Ja Min ^{[5
]}

Kwak, Jae-Yong ^{[6
]}

Lee, Myung-Won ^{[7
]}

Lee, Ho Sup ^{[8
]}

Kim, Seok Jin ^{[9
]}

Kim, Kihyun ^{[1
,10
]}

机构：

[1] Sungkyunkwan Univ, Sch Med, Div Hematol Oncol, Samsung Med Ctr,Dept Med, Seoul, South Korea

[2] Chonnam Natl Univ, Dept Hematol Oncol, Hwasun Hosp, Hwasun, South Korea

[3] Gyeongsang Natl Univ, Coll Med, Gyeongsang Natl Univ Hosp, Dept Internal Med, Jinju, South Korea

[4] Catholic Univ Korea, Catholic Hematol Hosp, Seoul St Marys Hosp, Dept Hematol,Coll Med, Seoul, South Korea

[5] Seoul Natl Univ, Seoul, South Korea

[6] Chonbuk Natl Univ, Med Sch, Jeonju, South Korea

[7] Chungnam Natl Univ, Coll Med, Dept Internal Med, Daejeon, South Korea

[8] Kosin Univ Gospel Hosp, Dept Internal Med, Busan, South Korea

[9] Samsung Med Ctr, Seoul, South Korea

[10] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-198947

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：7045 / 7046

页数：2

共 50 条

[1] Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA)
Roussel, Murielle
Moreau, Philippe
Hebraud, Benjamin
Laribi, Kamel
Jaccard, Arnaud
Dib, Mamoun
Slama, Borhane
Dorvaux, Veronique
Royer, Bruno
Frenzel, Laurent
Zweegman, Sonja
Klein, Saskia K.
Broijl, Annemiek
Jie, Kon-Siong
Wang, Jianping
Vanquickelberghe, Veronique
Boer, Carla de
Kampfenkel, Tobias
Gries, Katharine S.
Fastenau, John
Sonneveld, Pieter
LANCET HAEMATOLOGY, 2020, 7 (12): : E874 - E883
[2] Cyclophosphamide-bortezomib-dexamethasone compared with bortezomib-dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma
Figueiredo, A.
Atkins, H.
Mallick, R.
Kekre, N.
Kew, A.
McCurdy, A.
CURRENT ONCOLOGY, 2020, 27 (02) : E81 - E85
[3] Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial
Voorhees, Peter M.
Sborov, Douglas W.
Laubach, Jacob
Kaufman, Jonathan L.
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca
Costa, Luciano J.
Anderson, Larry D.
Nathwani, Nitya
Shah, Nina
Bumma, Naresh
Efebera, Yvonne A.
Holstein, Sarah A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Dinner, Shira
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Lin, Thomas S.
Usmani, Saad Z.
Richardson, Paul G.
LANCET HAEMATOLOGY, 2023, 10 (10): : E825 - E837
[4] Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
Voorhees, Peter M.
Kaufman, Jonathan L.
Laubach, Jacob
Sborov, Douglas W.
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca
Costa, Luciano J.
Anderson, Larry D., Jr.
Nathwani, Nitya
Shah, Nina
Efebera, Yvonne A.
Holstein, Sarah A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Murphy, Sean
Lutska, Yana
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
de Boer, Carla
Hoehn, Daniela
Lin, Thomas S.
Richardson, Paul G.
BLOOD, 2020, 136 (08) : 936 - 945
[5] The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma
Okazuka, Kiyoshi
Ishida, Tadao
Nashimoto, Junichiro
Uto, Yui
Sato, Kota
Miyazaki, Kanji
Ogura, Mizuki
Yoshiki, Yumiko
Abe, Yu
Tsukada, Nobuhiro
Suzuki, Kenshi
EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (02) : 110 - 115
[6] Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
Nooka, Ajay K.
Kaufman, Jonathan L.
Rodriguez, Cesar
Jakubowiak, Andrzej
Efebera, Yvonne
Reeves, Brandi
Wildes, Tanya
Holstein, Sarah A.
Anderson, Larry D., Jr.
Badros, Ashraf
Shune, Leyla
Chari, Ajai
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Bartlett, J. Blake
Vermeulen, Jessica
Lin, Thomas S.
Richardson, Paul G.
Voorhees, Peter
BLOOD CANCER JOURNAL, 2022, 12 (04)
[7] Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
Ajay K. Nooka
Jonathan L. Kaufman
Cesar Rodriguez
Andrzej Jakubowiak
Yvonne Efebera
Brandi Reeves
Tanya Wildes
Sarah A. Holstein
Larry D. Anderson
Ashraf Badros
Leyla Shune
Ajai Chari
Huiling Pei
Annelore Cortoos
Sharmila Patel
J. Blake Bartlett
Jessica Vermeulen
Thomas S. Lin
Paul G. Richardson
Peter Voorhees
Blood Cancer Journal, 12
[8] Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma
Shah, Jatin J.
Feng, Lei
Manasanch, Elisabet E.
Weber, Donna
Thomas, Sheeba K.
Turturro, Francesco
Shah, Nina
Popat, Uday R.
Nieto, Yago
Bashir, Qaiser
Munoz, Silvia C.
Landry, Ashley
Mendoza, Kathleen
Champlin, Richard E.
Qazilbash, Muzaffar H.
Orlowski, Robert Z.
BLOOD, 2015, 126 (23)
[9] Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial
O'Donnell, Elizabeth
Mo, Clifton
Yee, Andrew J.
Nadeem, Omar
Laubach, Jacob
Rosenblatt, Jacalyn
Munshi, Nikhil
Midha, Shonali
Cirstea, Diana
Chrysafi, Pavlina
Horick, Nora
Richardson, Paul G.
Raje, Noopur
LANCET HAEMATOLOGY, 2024, 11 (06): : e415 - e424
[10] Safety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): A phase I/II study
Richardson, P. G.
Lonial, S.
Jakubowiak, A.
Jagannath, S.
Raje, N.
Avigan, D.
Ghobrial, I. M.
Knight, R.
Esseltine, D.
Anderson, K. C.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

← 1 2 3 4 5 →